Denosumab — patient guide

This page covers denosumab — the 6-monthly bone-protective injection. If you have been prescribed Prolia (for osteoporosis) or Xgeva (for bone cancer or related specialist indications), this is your page.

---

Read this first — the one rule that makes denosumab different

Denosumab must not be stopped — or delayed beyond about 7 months from the previous dose — without a planned follow-on medicine.

This is the single most important sentence on the page. Unlike the bisphosphonate family (Fosamax, Actonel, Aclasta), which is retained in bone for years and tapers gradually after stopping, denosumab effect washes out over the 6 to 9 months after the last dose. What follows is a rebound rise in bone breakdown that can cause multiple spinal fractures within 6 to 18 months — particularly in people with a previous vertebral fracture or several years on therapy. The post hoc analysis of the FREEDOM trial and its extension (Cummings et al. 2018, J Bone Miner Res) and the European position statement (Tsourdi et al. 2017, Bone) lay out the evidence.

What this means in practice:

1. Never miss the 6-monthly Prolia injection by more than about a month without contacting the prescribing doctor.
2. Never stop denosumab on your own initiative, even temporarily for dental work, infection, or surgery.
3. If denosumab is ever to be stopped — for any reason — there must be a planned next medicine to consolidate the bone protection. Usually a follow-on antiresorptive arranged with the prescribing doctor at a defined point after the last dose. The conversation about what that looks like for your situation is part of the consult.

Denosumab is highly effective at reducing fracture risk while it is on board. The trade-off is that it requires either commitment to indefinite therapy with reliable 6-monthly attendance, or a planned exit. There is no third option.

---

Find your medicine

Generic name	Brand	Strength	How often	Who initiates
Denosumab	Prolia	60 mg subcutaneous injection	Every 6 months	GP, endocrinologist, or geriatrician (osteoporosis)
Denosumab	Xgeva	120 mg subcutaneous injection	Every 4 weeks	Oncology specialist (bone metastases, giant cell tumour, cancer-related high calcium)

Same active ingredient — very different doses, very different schedules, very different prescribing pathways. Prolia and Xgeva are not interchangeable, and the risk profile (especially the rate of jaw complications) scales with the dose.

Closely related — the bisphosphonate family (Fosamax, Actonel, Aclasta, Bonviva). Different drug class with the same end-point (slowing bone breakdown). Not interchangeable with denosumab. Switching between the two is a coordinated decision because of the rebound bone-loss issue when denosumab is stopped without a follow-on agent. See the bisphosphonates page for the comparison.

---

What it treats

Denosumab is prescribed in several distinct situations. Your reason may be one or more of:

• Postmenopausal osteoporosis — the most common reason. A DEXA T-score at or below -2.5, or a previous fragility fracture, is the usual trigger.
• Male osteoporosis — same threshold logic, fewer years of trial data than in postmenopausal women.
• Glucocorticoid-induced osteoporosis — long-term oral steroid use (prednisolone, dexamethasone) accelerates bone loss. Denosumab is protective.
• Bone-loss on cancer hormone therapy — men on androgen-deprivation therapy for prostate cancer, women on aromatase inhibitors for breast cancer.
• Bone metastases, giant cell tumour, hypercalcaemia of malignancy refractory to bisphosphonates — these are specialist indications, treated with Xgeva at the higher dose.

The mechanism is the same across all of these. The dose, cadence, and prescribing pathway differ by indication.

---

The basics

1. Never let a Prolia dose drift beyond about a month past its due date without contacting the prescribing doctor. See the rebound block above.
2. Confirm vitamin D and calcium adequacy BEFORE every dose, not only the first.
3. See your dentist BEFORE starting if at all reasonably possible. Tell every dentist you ever see — forever — that you are on or have ever been on denosumab.
4. New persistent thigh, groin, or hip pain on therapy gets imaged urgently. Tell us.
5. Tingling around the mouth, hands, or feet, or muscle cramps in the days after a dose is low calcium until proven otherwise. Phone us.

---

What to expect

• The Prolia injection itself takes seconds — a prefilled syringe given under the skin of the upper arm, thigh, or abdomen by a GP, practice nurse, or pharmacist. No infusion line, no ritual, no fasting.
• Most people feel nothing different day-to-day. The medicine works on bone over months and years; you do not feel it.
• A bone-density (DEXA) scan at baseline, repeated at around 2 years, is standard. Some clinicians use bone-turnover blood markers in between.
• For the first dose, calcium and vitamin D adequacy are confirmed beforehand. For subsequent doses, the same check is repeated — particularly important in winter, in kidney impairment, in malabsorption, or if any new medicine (PPI, loop diuretic, cinacalcet) has been started since the last injection.
• Mild injection-site tenderness or a small red mark for a day or two is common and settles on its own.

---

Tap any section below to expand the detail.

How does it work?

Bone is constantly remodelled. The cells that build bone (osteoblasts) and the cells that break it down (osteoclasts) normally work in balance. After menopause, with long-term steroids, with some cancer treatments, the breakdown side runs ahead of the building side, and bone density falls.

Denosumab is a monoclonal antibody that binds RANK ligand — a signal that osteoblasts normally send to recruit and activate osteoclasts. Block that signal, and the osteoclasts do not get activated. Bone breakdown drops sharply within days of an injection, bone density rises, and fracture risk falls.

The effect is fast on, fast off. That is the strength of the medicine (it works promptly and continues working at full effect for the full 6-month dosing interval) and it is also the source of the rebound problem at discontinuation. The effect does not linger after the last dose the way a bisphosphonate does — which is why the exit-plan rule matters.

The reference trials are FREEDOM (Cummings et al. NEJM 2009) for the initial 3-year fracture data and the FREEDOM extension (Bone et al. Lancet Diabetes Endocrinol 2017) for the 10-year safety and efficacy continuation.

This is structural protection, not pain relief. You will not feel it working. The way we know it is working is the DEXA trajectory, the absence of fragility fracture, and sometimes the blood markers of bone turnover.

Side effects in detail

Common

• Mild injection-site reaction — a small red mark, mild tenderness, or itch in the first 48 hours that settles on its own.
• Musculoskeletal aches in the first weeks after a dose, usually settling.
• Mild upper-respiratory symptoms were noted at slightly higher rates than placebo in FREEDOM.

Uncommon

• Low calcium (hypocalcaemia) in the days after a dose — particularly if vitamin D was not adequate beforehand, in kidney impairment, in malabsorption, or with co-prescribed cinacalcet. Symptoms: tingling around the mouth, fingers, or toes; muscle cramps; unusual fatigue. Phone us promptly.
• Cellulitis at the injection site — spreading redness, warmth, or pain at the site, particularly several days after the dose. Documented in FREEDOM. Same-day review.
• Dermatitis and eczema-like rashes elsewhere on the body — usually mild, occasionally widespread. A new widespread rash, blistering, or any involvement of mouth, eyes, or genital mucosa needs same-day review.
• Modest signal for serious infection — mostly characterised at the 120 mg Xgeva oncology dose in patients who are often concurrently immunosuppressed. Worth knowing rather than a contraindication at the Prolia dose.

Rare but action-driven

• Osteonecrosis of the jaw (ONJ). Around 1 in 1000 to 1 in 10,000 patient-years at the Prolia 60 mg six-monthly dose; around 1 to 2 percent per year on the Xgeva 120 mg monthly oncology dose. Risk goes up with dental extractions, poor oral hygiene, smoking, glucocorticoid co-therapy, and chemotherapy. Symptoms — non-healing tooth socket, exposed bone in the mouth, jaw pain, jaw numbness — need urgent dental and medical review. International consensus is summarised in the Khan et al. 2015 J Bone Miner Res paper.
• Atypical femoral fracture (AFF). Rare and the risk rises slightly with longer duration of therapy. New persistent thigh, groin, or hip pain — one or both sides — that develops gradually and does not settle is a stress-fracture warning until imaged. X-ray and often MRI of both femurs. The reference is the ASBMR task force 2nd report (Shane et al. 2014, J Bone Miner Res).
• Severe allergic reaction — sudden swelling of face, lips, tongue, or throat; difficulty breathing; feeling faint after an injection. Rare. Triple-zero situation.

Rebound vertebral fracture on discontinuation — covered at the top of the page and in its own section below.

Drugs, food, and alcohol

Tell us or your pharmacist before combining denosumab with:

• Calcium-lowering drugs — cinacalcet, recent intravenous bisphosphonate, loop diuretics in kidney impairment. Additive risk of low calcium after a denosumab dose. Re-check calcium and vitamin D before the injection if any have been started or changed since the last one.
• Glucocorticoids (prednisolone, dexamethasone) — accelerate bone loss and amplify ONJ risk. Often the reason denosumab was started in the first place; the medicine is protective, ONJ vigilance is heightened.
• Chemotherapy, particularly anti-angiogenic agents (bevacizumab, sunitinib) — substantially amplify ONJ risk at the Xgeva oncology dose. This is an oncology-specialist domain.
• Immunosuppressants and biologics — modest signal for increased serious infection in pooled data, mostly at the Xgeva dose.
• Proton-pump inhibitors (omeprazole, esomeprazole, pantoprazole, rabeprazole, lansoprazole) — long-term use has its own bone-density signal independent of denosumab. Worth periodically reviewing whether the PPI is still needed.
• Bisphosphonates — do not co-administer for the same indication. Switching between the two is a specialist-coordinated decision; a bisphosphonate is often the planned follow-on antiresorptive after denosumab discontinuation.

Notable absence of one whole class of interaction — denosumab is a monoclonal antibody, cleared by the immune system rather than the liver. There are no clinically significant cytochrome-P450 (CYP) interactions of the kind that complicate many small-molecule medicines. This is a real advantage in polypharmacy.

Food. No food restrictions. No empty-stomach rule. No upright posture rule. Calcium can be taken at any time relative to the injection — unlike with oral bisphosphonates, calcium does not block absorption (because denosumab is not absorbed from the gut).

Alcohol. Light to moderate use is not a hard problem. Heavy alcohol use accelerates bone loss independently of the medicine and is worth addressing.

Generic substitution. Biosimilar denosumab products are emerging internationally. At the time of writing, brand availability in Australia is the originator Prolia (osteoporosis) and Xgeva (oncology). Your pharmacist will tell you what is currently dispensed under the PBS listing.

Monitoring — what blood tests and when

• Before starting: vitamin D level (target 25-hydroxyvitamin D 75 to 100 nmol/L), calcium, kidney function (eGFR), and a DEXA scan if not already done. Dental review.
• Before every dose: vitamin D and calcium adequacy. This is not optional and not only-for-the-first-dose.
• After each dose: awareness of low-calcium symptoms in the days after. Routine post-dose blood testing is not standard in low-risk patients but is recommended at 1 to 2 weeks post-dose in higher-risk groups (eGFR under 30, malabsorption, hypoparathyroidism, undiagnosed coeliac, on cinacalcet, on loop diuretic).
• DEXA: baseline and around 2 years after starting, then individualised based on trajectory and risk.
• Dental review: before starting if possible; routine cleans every 6 months; tell every dentist about the denosumab history.
• Message us if you start a new medicine (including over-the-counter or supplements), have an unexplained tooth-extraction socket that will not heal, develop new persistent thigh / groin / hip pain, develop any unexplained mouth pain, swelling, or exposed bone, or if a Prolia dose looks like it will be delayed beyond its due date.

The discontinuation rule — and why an exit plan must exist before you ever need it

This is the longer version of the block at the top of the page, and the most important section here.

Why denosumab is different from a bisphosphonate at the moment of stopping. A bisphosphonate is retained in bone for years; its anti-resorptive effect tapers gradually after the last dose, which is the basis for the treatment-holiday concept. Denosumab is not retained that way. Its effect washes out over the 6 to 9 months after the last dose. What follows is a rebound rise in bone breakdown — bone resorption markers overshoot pre-treatment baseline before settling. The clinical translation is a window of elevated fracture risk, predominantly at the spine, lasting roughly 6 to 18 months. Multiple vertebral fractures during a single rebound episode are well documented.

Who is at higher risk in the rebound window. People who have already had a vertebral fracture before or during denosumab therapy. People who have been on denosumab for longer (more bone-density gain to lose). Older age. The classic at-risk scenario is the patient who has done well on denosumab for several years, decides (or is advised) to stop because “the bones are good now,” and is offered nothing in its place.

The standard approach if denosumab is ever to be stopped. A planned follow-on antiresorptive medicine to consolidate the gains. The specific regimen is a decision your prescribing doctor will make based on your kidney function, fracture history, dental status, and the rest of your situation — there is no single right answer that fits every person. The non-negotiable principle is that the next medicine is arranged in advance, with a defined start date relative to your last denosumab dose. The conversation about which medicine, when, and for how long, is part of the consult.

What this means for everyday adherence. Treat the 6-monthly Prolia injection (or 4-weekly Xgeva injection) as a non-negotiable diary item. Travel plans, dental work, infections, surgery, life chaos — none of these are reasons to silently skip a dose. They are all reasons to phone us early and rearrange around the dosing window.

Delayed beyond 7 months equals the same risk as stopping. This is the part many patients (and some health professionals) do not fully appreciate. The rebound window does not require formal discontinuation; it opens whenever the effect washes out. A dose delayed by 2 to 3 months without coverage is operationally the same as deciding to stop.

Pregnancy and breastfeeding

Denosumab is a monoclonal antibody — an IgG molecule that crosses the placenta in the second and third trimesters of pregnancy and persists in the body for months after the last dose. This combination of placental transfer plus prolonged retention is the class-distinguishing feature for pregnancy planning.

• Already pregnant: contact us promptly. Denosumab is not used in pregnancy.
• Breastfeeding: generally avoided; limited safety data.
• Planning future pregnancy at any timeframe: this is a conversation BEFORE starting denosumab, not after. Effective contraception throughout therapy AND for at least 5 months after the last dose is recommended. If pregnancy is on the horizon at any point, an alternative bone-protective approach without the long retention of effect is worth weighing.

For the postmenopausal majority audience reading this page, this section is informational — worth knowing the principle for daughters, sisters, or younger relatives in whom the question may come up.

Dental care — the standing rule and the critical caveat

The single most actionable thing to minimise jaw-related risk on denosumab:

• Before starting: book a dental review. Complete any planned extractions, implants, or major work first if possible, and allow healing (usually a few weeks to a few months).
• During therapy: routine cleans every 6 months. Meticulous home oral hygiene. Address any new dental issues promptly rather than waiting.
• Forever after: every dentist you ever see needs to know you are on, or have ever been on, denosumab. This affects how they plan extractions and implants.
• Symptoms to flag urgently: non-healing tooth socket (extraction site that has not healed at 6 to 8 weeks), exposed bone visible in the mouth, jaw pain, jaw numbness, loose teeth without an obvious cause.

The critical caveat — do NOT routinely interrupt denosumab for dental work. This is the opposite of what many patients (and some dentists) intuitively assume. Interrupting denosumab opens the rebound bone-loss window. Instead, the timing of any invasive dental work is coordinated with the prescribing doctor — usually scheduled within a window where the next denosumab dose can still be given on time. If the dental work is genuinely urgent, the bone-protection conversation runs in parallel rather than instead.

If you are switching from a bisphosphonate to denosumab — or the other way

Switching between denosumab and the bisphosphonate family is common and well-described, but the order matters and the timing matters.

• Bisphosphonate to denosumab is sometimes done because of oesophageal intolerance of oral bisphosphonates, swallowing difficulty, kidney function below the comfortable range for zoledronic acid, or interval fracture on bisphosphonate therapy. The switch itself is straightforward but is a specialist-coordinated decision.
• Denosumab to bisphosphonate is the more important direction for this page — because it is the standard exit pathway when denosumab is being stopped. The bisphosphonate consolidates the bone-density gain and prevents the rebound. The specific timing and the specific bisphosphonate regimen are individualised; the principle is that the follow-on medicine is planned and arranged in advance, with a defined relationship to the last denosumab dose.

The conversation about which switch direction makes sense for you, and when, is part of the consult.

Cost

Prolia is PBS-listed under Streamlined Authority for osteoporosis (DEXA T-score at or below -2.5, OR documented minimal-trauma fracture). Xgeva is PBS-listed under Authority Required for specialist oncology indications. From 1 January 2026, the PBS co-payment is:

• General patient: up to $25.00 per script
• Concession card holder: up to $7.70 per script

The Prolia injection itself is given by a GP, practice nurse, or pharmacist in the rooms — there may be a separate consultation fee for the visit, which varies by clinic and Medicare item arrangements. Your clinic can tell you the actual out-of-pocket upfront. The Xgeva infusion is given in a specialist setting and the cost arrangement is handled by the oncology team.

---

The integrative view

Most of the patients I see want to do everything they reasonably can in addition to taking the medicine. This section is the longer version of that conversation. Bone is a living tissue — the medicine slows breakdown, your terrain decides whether the building side can keep up.

Two principles. First: denosumab works for fracture prevention in the people it is indicated for, and the evidence (FREEDOM and its 10-year extension) is solid. Lifestyle work also moves bone density and fracture risk. The two are not alternatives. Second: the medicine addresses the bone-cell biology, but most fragility fractures begin with a fall. The package matters more than any single piece of it.

Vitamin D — the input that determines whether the next dose goes smoothly

Vitamin D adequacy is not optional on this medicine. It is the main avoidable cause of low calcium after a denosumab dose, and the check happens before every injection — not only the first.

• Target serum 25-hydroxyvitamin D 75 to 100 nmol/L before every dose.
• Maintenance dose is typically 1000 to 2000 IU per day (25 to 50 micrograms). Higher loading doses are sometimes used if you are deficient at baseline.
• Check the level before starting, again at around 6 to 12 months, then yearly — or more often if you live above the 35th parallel, work indoors year-round, cover for cultural or sun-safety reasons, or have a malabsorption condition.

Calcium — food first, supplement only if short

• Target total intake (food plus supplement combined) around 1000 to 1200 mg per day for postmenopausal women and men over 70.
• Food-first sources: dairy (a cup of milk is around 300 mg; yoghurt is similar); fortified plant milks (check the label — usually 240 to 300 mg per cup); sardines or salmon with bones (around 300 mg per small tin); calcium-set tofu (around 300 mg per 100 g); leafy greens (kale, bok choy — around 100 mg per cup cooked).
• Supplement only if food intake reliably falls short. 500 to 600 mg of supplemental calcium with food covers most gaps; doses above 1000 mg per day from supplements have been associated with a cardiovascular signal in some analyses and are not usually needed.
• Unlike with oral bisphosphonates, timing of calcium does not interact with the denosumab injection — the antibody is administered subcutaneously, not absorbed from the gut. Take calcium when it suits the rest of your routine.

Protein — the load-bearing nutrient for bone matrix

• Around 1.0 to 1.2 g/kg/day for older adults on bone-protective therapy. For a 65 kg woman, that is roughly 65 to 78 g of protein a day, spread across meals.
• Bone strength depends on muscle that loads it. Sarcopenia and osteoporosis travel together; protein at every meal supports both.

Magnesium — check rather than supplement reflexively

• Supports parathyroid hormone function and bone matrix mineralisation.
• Routine class-level supplementation is not required. Worth checking the level if calcium has run low repeatedly, on a long-term PPI, on a loop or thiazide diuretic, or with a GI absorption issue (coeliac, IBD, post-bariatric surgery).

Vitamin K2 (menaquinone) — modest evidence, conversation-based

• Supports osteocalcin carboxylation. Some RCT signal for bone mineral density in postmenopausal women; effect size is modest and AU guidelines do not currently include it as a routine recommendation. Discuss case-by-case rather than blanket-recommend.

Weight-bearing and resistance training — independent fracture-risk reduction

• The medicine works on bone cells. Mechanical load works on the same bone — and on the muscle and balance that prevent the fall in the first place.
• Weight-bearing aerobic activity (brisk walking, dancing, jogging if appropriate, stair climbing) most days.
• Progressive resistance training 2 to 3 sessions per week — the load is what bone responds to. The LIFTMOR trial in postmenopausal women showed high-intensity resistance training improved bone density and was safe in supervised settings. An exercise physiologist or qualified personal trainer can help calibrate.

Falls prevention — the medicine works on bone, but the fracture begins with the fall

Most fragility fractures do not happen in the gym. They happen on a rug, on a wet floor, on a step in the dark, after a quick blood-pressure drop on standing.

• Otago Exercise Programme — strength + balance training, well-evidenced for falls reduction in older adults.
• Tai chi — meta-analyses show meaningful falls reduction.
• Home hazard review — loose rugs, dim stairwells, slippery bathrooms, footwear.
• Vision check — when was your last optometry review?
• Medication review — sedatives, sleeping tablets, some blood-pressure medicines and antidepressants can increase falls risk. Worth periodically reviewing the list.
• Postural blood-pressure check — a drop on standing is a falls risk and is treatable.

Comparison with the bisphosphonate family — a neutral view

The choice between denosumab and a bisphosphonate is individualised. Neither class is “better” in the abstract; the trade-offs read differently depending on your situation.

• Reflux or swallowing difficulty, or weekly-tablet adherence is the obstacle. Denosumab sidesteps the oral ritual entirely.
• Kidney function under about 35. Intravenous zoledronic acid is generally avoided; denosumab is sometimes preferred (with intensive calcium and vitamin D surveillance), though under 30 the calcium-after-dose risk rises.
• Reliable 6-monthly recall and a clear exit plan. Denosumab requires both. If your life makes 6-monthly attendance unreliable, or if a planned exit is unclear, a bisphosphonate (which allows the treatment-holiday concept) is more forgiving.
• Future pregnancy possible. Bisphosphonates are retained in bone for years; denosumab clears within months but has its own pregnancy considerations. Neither is ideal — discuss BEFORE starting either class.
• Polypharmacy with many CYP-metabolised medicines. Denosumab has no significant CYP interactions; this can be a real advantage in older patients on many medicines.

The full bisphosphonate page is here for the matched comparison.

---

Track these between now and your next visit

• The date your next dose is due — and contact us early if it looks like it will be delayed.
• Any new persistent thigh, groin, or hip pain — when it started, which side, how it behaves with walking vs rest.
• Any new dental issues — non-healing socket, jaw pain, loose tooth, mouth swelling.
• Any tingling around the mouth, in the hands or feet, or muscle cramps in the days after a dose.
• Any new medicine or supplement you have started, including over-the-counter pain relief and any “bone health” supplement.
• Falls — any near-falls or actual falls since the last visit, and what was happening when it happened.

Bring the list to your review appointment.

---

This is general information, not personal medical advice. Every patient is different. Decisions about your medicines — which one, what dose, when to stop, what to combine with — are made with the doctor who prescribed them. If anything on this page appears to contradict advice from your treating doctor, follow your doctor; they have context about your situation that this page cannot.

Reading this page does not establish a doctor-patient relationship with Dr Hoebing Lo. If you are not a current patient, please discuss your medicines with your own GP, specialist, or pharmacist.

About the integrative content. The lifestyle, dietary, and complementary recommendations on this page summarise current published research. Effect sizes are approximations from clinical studies — individual response varies, and real-world results are commonly smaller than trial results because day-to-day life differs from study conditions. Supplements and herbal products are not interchangeable with prescribed medication and can interact with it. Talk to your doctor and pharmacist before starting any new supplement, herbal product, or significant change in diet.

Currency. This page reflects clinical practice as of the last-reviewed date. Medicine evolves; specific details may date between reviews. Pricing shown is indicative; confirm with your pharmacist.

No commercial relationships. Dr Hoebing Lo has no financial or commercial relationship with the manufacturer of any medicine, brand, or supplement mentioned on this page.

Emergencies. Sudden swelling of face, lips, tongue, or throat; difficulty breathing; chest pain; severe dizziness or fainting; or new severe abdominal pain after starting a new medicine — call 000 or go to your nearest emergency department. Do not wait, and do not message us first.